Skip to main content
Livermore
Livermore
ZHEN

Camber Capital Management LP

SEC CIK
0001444043
Latest filing
Aug 14, 2025

The latest 13F from Camber Capital Management LP covers Q2 2025 (filed Aug 14, 2025): 23 long positions worth $717.9M. The top 10 holdings make up 78.9% of the portfolio, and the largest is Zimmer Biomet Holdings, Inc. (ZBH) at 12.7%. Livermore has 18 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2025

Share counts compared with Q1 2025: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
4
Est. +$129.1M
Added
1
Est. +$5.50M
Reduced
16
Est. −$612.8M
Sold out
9
Est. −$303.5M

Top 5 holdings

Share of this quarter's portfolio value

  1. ZBHZimmer Biomet Holdings, Inc.
    12.7%$91.2MHistory
  2. BAXBaxter International Inc
    12.0%$86.3MHistory
  3. HUMHumana Inc
    10.2%$73.3MHistory
  4. CVSCVS Health Corp
    10.1%$72.4MHistory
  5. GMEDGlobus Medical Inc
    6.6%$47.2MHistory

Share of portfolio

Top 5 holdings and the other 18 positions, by share of portfolio value

  1. ZBH12.7%
  2. BAX12.0%
  3. HUM10.2%
  4. CVS10.1%
  5. GMED6.6%
  6. Other 18 positions48.4%

Biggest buys

New and added positions, by estimated amount bought

  1. ICLRIcon PLC
    +$43.6MNewHistory
  2. MRKMerck & Co., Inc.
    +$39.6MNewHistory
  3. UNHUnitedHealth Group Inc
    +$31.2MNewHistory
  4. APLSApellis Pharmaceuticals, Inc.
    +$14.7MNewHistory
  5. BMRNBiomarin Pharmaceutical Inc
    +$5.50MAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. ICLRIcon PLC
    +6.08 pp0.0% → 6.1%History
  2. MRKMerck & Co., Inc.
    +5.51 pp0.0% → 5.5%History
  3. UNHUnitedHealth Group Inc
    +4.35 pp0.0% → 4.3%History
  4. BMRNBiomarin Pharmaceutical Inc
    +2.39 pp2.2% → 4.6%History
  5. APLSApellis Pharmaceuticals, Inc.
    +2.05 pp0.0% → 2.0%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. ZBHZimmer Biomet Holdings, Inc.
    −$114.0MReducedHistory
  2. HUMHumana Inc
    −$103.9MReducedHistory
  3. BAXBaxter International Inc
    −$87.8MReducedHistory
  4. CVSCVS Health Corp
    −$82.8MReducedHistory
  5. PTCTPTC Therapeutics, Inc.
    −$76.4MSold outHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. PTCTPTC Therapeutics, Inc.
    −4.77 pp4.8% → 0.0%History
  2. CICigna Group
    −4.11 pp4.1% → 0.0%History
  3. QGENQiagen N.V.
    −3.51 pp3.5% → 0.0%History
  4. SRPTSarepta Therapeutics, Inc.
    −3.19 pp3.2% → 0.0%History
  5. ZBHZimmer Biomet Holdings, Inc.
    −3.18 pp15.9% → 12.7%History

Metrics

13F metrics for Q2 2025, computed only from the numbers in the filings. Definitions below.

Portfolio value
$717.9M
−$884.7M (−55.2%) vs. prior quarter
Positions
23
−5 vs. prior quarter
Top 10 concentration
78.9%
Top 10 as share of value
Turnover
11.6%
Q2 2025, one quarter
Average holding period
7.6 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

18 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $3.07B (Q2 2023)

Q1 2021: $2.52BQ2 2021: $2.55BQ3 2021: $2.69BQ4 2021: $2.59BQ1 2022: $2.76BQ2 2022: $2.30BQ3 2022: $2.99BQ4 2022: $2.86BQ1 2023: $2.93BQ2 2023: $3.07BQ3 2023: $2.79BQ4 2023: $2.86BQ1 2024: $2.86BQ2 2024: $2.59BQ3 2024: $2.57BQ4 2024: $2.56BQ1 2025: $1.60BQ2 2025: $717.9M
Q1 2021Q2 2025
13F filings of Camber Capital Management LP by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2025Aug 14, 202523$717.9MZBHBAXHUMvs. Q1 2025SEC
Q1 2025May 15, 202528$1.60BZBHBAXHUMvs. Q4 2024SEC
Q4 2024Feb 14, 202536$2.56BMDTVTRSZBHvs. Q3 2024SEC
Q3 2024Nov 14, 202432$2.57BZBHMDTBAXvs. Q2 2024SEC
Q2 2024Aug 14, 202435$2.59BZBHBAXMDTvs. Q1 2024SEC
Q1 2024May 15, 202434$2.86BZBHUHSBAXvs. Q4 2023SEC
Q4 2023Feb 14, 202436$2.86BUHSTHCZBHvs. Q3 2023SEC
Q3 2023Nov 14, 202339$2.79BUHSTHCZBHvs. Q2 2023SEC
Q2 2023Aug 14, 202338$3.07BUHSTHCVTRSvs. Q1 2023SEC
Q1 2023May 15, 202340$2.93BSNYUHSTHCvs. Q4 2022SEC
Q4 2022Feb 14, 202338$2.86BSNYUHSVTRSvs. Q3 2022SEC
Q3 2022Nov 14, 202242$2.99BSNYVTRSUHSvs. Q2 2022SEC
Q2 2022Aug 15, 202240$2.30BVTRSSNYZBHvs. Q1 2022SEC
Q1 2022May 16, 202237$2.76BVTRSUHSSNYvs. Q4 2021SEC
Q4 2021Feb 14, 202236$2.59BVTRSUHSMRKvs. Q3 2021SEC
Q3 2021Nov 15, 202134$2.69BUHSWBATHCvs. Q2 2021SEC
Q2 2021Aug 16, 202130$2.55BTHCWBAVTRSvs. Q1 2021SEC
Q1 2021May 17, 202131$2.52BCHNGWBAUHS–SEC

13D and 13G filings

Companies where Camber Capital Management LP reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

Camber Capital Management LP does not currently report owning 5% or more of any company.

Latest filings

45 filings on file made by Camber Capital Management LP or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by Camber Capital Management LP
CompanyFiled (ET)FormStakeChangeEvent dateFiling
ZIMVZimVie Inc.Aug 27, 202512:02 PM ET13G/A0.00%0 shares−5.70 ppfrom 5.70%Below 5%Jul 21, 2025SEC
ZIMVZimVie Inc.Aug 14, 20259:11 PM ET13G/A5.70%1.60M shares−1.10 ppfrom 6.80%Jun 30, 2025SEC
BKDBrookdale Senior Living Inc.May 16, 20259:23 AM ET13G/A2.70%6.25M shares0.00 ppfrom 2.70%Below 5%Mar 31, 2025SEC
OSUROrasure Technologies IncMay 15, 20254:16 PM ET13G/A1.20%900.0K shares–Below 5%Mar 31, 2025SEC
INGNInogen IncMay 15, 20254:16 PM ET13G/A3.70%975.0K shares–Below 5%Mar 31, 2025SEC
ZIMVZimVie Inc.May 15, 20254:15 PM ET13G/A6.80%1.89M shares−3.07 ppfrom 9.87%Mar 31, 2025SEC
BKDBrookdale Senior Living Inc.May 15, 20254:15 PM ET13G/A2.70%6.25M shares−5.78 ppfrom 8.48%Below 5%Mar 31, 2025SEC
PTCTPTC Therapeutics, Inc.Feb 14, 20258:35 AM ET13G/A4.15%3.20M shares–Below 5%Dec 31, 2024SEC
PBYIPuma Biotechnology, Inc.Feb 14, 20258:34 AM ET13G/A0.00%0 shares–Below 5%Dec 31, 2024SEC
BKDBrookdale Senior Living Inc.Feb 14, 20258:33 AM ET13G/A8.48%17.2M shares–Dec 31, 2024SEC
ZIMVZimVie Inc.Feb 14, 20258:32 AM ET13G/A9.87%2.73M shares–Dec 31, 2024SEC
MYGNMyriad Genetics IncFeb 14, 20258:32 AM ET13G/A3.41%3.10M shares–Below 5%Dec 31, 2024SEC
SLDBSolid Biosciences Inc.Feb 14, 20258:30 AM ET13G/A0.00%0 shares–Below 5%Dec 31, 2024SEC
QTRXQuanterix CorpFeb 14, 202413G/AOld format–––SEC
MYGNMyriad Genetics IncFeb 14, 202413G/AOld format–––SEC
INGNInogen IncFeb 14, 202413G/AOld format–––SEC
ZIMVZimVie Inc.Feb 14, 202413G/AOld format–––SEC
BKDBrookdale Senior Living Inc.Feb 14, 202413G/AOld format–––SEC
PBYIPuma Biotechnology, Inc.Feb 14, 202413G/AOld format–––SEC
PTCTPTC Therapeutics, Inc.Oct 30, 202313GOld format–New–SEC